03-07-05

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Nathan Kane et al.

Serial No.:

10/700,146

Group No.:

3754

Filed:

11/03/2003

Examiner:

Not Yet Assigned

For:

METHODS FOR MANIPULATING SMALL AMOUNTS OF SOLIDS

Attorney Docket Number:

TPIP024

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandřia, VA 22313-1450

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
WITHIN THREE MONTHS OF FILING APPLICATION OR BEFORE MAILING OF A
FIRST OFFICE ACTION ON THE MERITS (37 CFR 1.97(b))

Dear Sir:

Applicant submits herewith patents, publications or other information of which, in good-faith judgment of the Applicant, may be relevant to the subject matter claimed in the above-identified application and in respect of which, there may be a duty to disclose. Applicant submits these documents in compliance with the duty of disclosure as defined in 37 CFR §1.56, §1.97, and §1.98. The Examiner is requested to make these citations of official record in the present application.

This Information Disclosure Statement is not to be construed as a representation that a search has been made, that additional information material to the examination of this application does not exist, or that these references indeed constitute prior art.

The Information Disclosure Statement transmitted herewith is being filed *after* three months of the filing date of this national application but *before* the mailing date of the first Office action on the merits. Accordingly, it is believed that no fees are due in connection with

CERTIFICATE OF MAILING BY EXPRESS MAIL

I hereby certify that under 37 CFR §1.10 that this correspondence is being deposited on 
with the United States Postal Service as Express Mail Post Office to Addressee with sufficient postage in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313
1450.

Kristin Kaberry

the filing of this Information Disclosure Statement. However, if it is determined that any fees are due, the Commissioner is hereby authorized to charge such fees to Deposit Account No. 502626.

Pursuant to OG Notice dated August 5, 2003, copies of cited U.S. patents and patent application publications as listed in Form PTO-1449 are not enclosed, as this application was filed after June 30, 2003. However, copies of foreign patent documents are enclosed in accordance with 37 CFR 1.98 (a)(2). Should the Examiner require a copy of a reference listed, the Examiner is invited to contact the undersigned.

A copy of a PCT International Search Report from the counterpart application is enclosed. Cumulative patents or publications identified in the attached PCT Search Report are not enclosed.

I hereby certify that each item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the statement.

The Applicant respectfully requests that:

- a. The Examiner consider the cited information in reaching a determination concerning the patentability of the pending claims; and
- b. The enclosed Form PTO-1449 be signed by the Examiner to evidence that the cited information has been fully considered by the Patent and Trademark Office during the examination of this application.

Respectfully submitted,

, 2005

Transform Pharmaceuticals, Inc.

29 Hartwell Avenue Lexington, MA 02421

Telephone: (781) 674-7948 Facsimile: (781) 863-7208 Christopher Olson, Patent Agent

Reg. No. 55,510

PTO/SB/08A (08-03)

Approved for use through 07/31/2008. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

ork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Under the Reservork Reduction Act of 1995, no personal Programme of 1995, no personal Program

Sheet

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known			
Application Number	10/700,146	104.1	
Filing Date	11/03/2003		
First Named Inventor	Nathan Kane		
Art Unit	3754		
Examiner Name			
Attorney Docket Number	TPIP024		

Examiner	Cite	December 1	Publication Date	DOCUMENTS	I D O-1 1/ 14/
Examiner Initials*	No.1	Document Number  Number-Kind Code <sup>2 (# known)</sup>	MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		US- 09/628,667	07-28-2000	Putnam et al.	
		<sup>US-</sup> 20020015666	02-07-2002	Vann et al.	
		<sup>US-</sup> 20020048610	04-25-2002	Cima et al.	
		<sup>US-</sup> 20030087442	05-08-2003	Popa-Burke et al.	
		<sup>US-</sup> 20040168529	09-02-2004	Carlson et al.	
		<sup>US-</sup> 6,096,156	08-01-2000	Morin et al.	
		<sup>US-</sup> 6,221,268	04-24-2001	Li et al.	
		<sup>US-</sup> 6,284,329	09-04-2001	Matienzo et al.	
		<sup>US-</sup> 6,674,022	01-06-2004	Fermier et al.	
		<sup>US-</sup> 6,686,207	02-03-2004	Tupper et al.	
		<sup>US-</sup> 6,805,175	10-19-2004	Pinkas et al.	
		US-			

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No.1	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	
		Country Code <sup>3</sup> "Number <sup>4</sup> "Kind Code <sup>5</sup> (if known)	MM-DD-YYYY		Or Relevant Figures Appear	T
		WO 01/51919	07-19-2001	TransForm Pharm		
		WO 03/100390	12-04-2003	Symyx Technol.		
			1	1		

Examiner	Date	
Signature	Considered	1
		i e

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.